

## Brain tumours (primary) and brain metastases in adults

Committee membership, register of declarations of interest and NGA technical team

*NICE guideline NG99*

*July 2018*

*Final*

*These evidence reviews were developed by the National Guideline Alliance, hosted by the Royal College of Obstetricians and Gynaecologists*



---

## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© NICE 2018. All rights reserved. Subject to [Notice of rights](#).

ISBN: 978-1-4731-3001-2

## **Contents**

|  |           |
|--|-----------|
| <b>Committee membership list .....</b>           | <b>5</b>  |
| <b>Register of declarations of interest.....</b> | <b>6</b>  |
| <b>NGA technical team .....</b>                  | <b>48</b> |

# Committee membership list

The Committee will operate as an advisory Committee to NICE's Board, developing a guideline on brain tumours (primary) and brain metastases in adults.

The terms of reference and standing orders for the Committee can be found in Appendix D of [Developing NICE guidelines: the manual](#).

| Name                 | Title   | Specialist area            |
|----------------------|---|----------------------------|
| Tom Roques           | Consultant clinical oncologist, Norfolk and Norwich University Hospital NHS Foundation Trust  | Chair                      |
| Garth Cruickshank    | Professor of Neurosurgery and Consultant Neurosurgeon, Queen Elizabeth Hospital, Birmingham   | Clinical Lead              |
| Alison Cameron       | Clinical Oncology Consultant, Bristol Haematology and Oncology Centre   | Clinical Oncologist        |
| Catherine Derbyshire | Consultant Clinical Neuropsychologist: Neuro-oncology, Hull and East Yorkshire NHS Trust and Leeds Teaching Hospitals Trust                 | Allied Health Professional |
| Colin Watts          | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon, Addenbrookes Hospital, Cambridge   | Neuro-oncology surgeon     |
| David Summers        | Consultant in Diagnostic Neuroradiology, Department of Clinical Neurosciences, Western General Hospital, Edinburgh.                         | Neuro-radiologist          |
| Eileen Andrews       | Macmillan Neuro Oncology Clinical Nurse Specialist, National Hospital for Neurology and Neurosurgery, UCLH                                  | Clinical Nurse Specialist  |
| Helen Bulbeck        | Patient / Carer Member  | Patient/Carer Member       |
| Ingela Oberg         | Macmillan Neuro Oncology Clinical Nurse Specialist, Addenbrooke's Hospital, Cambridge   | Clinical Nurse Specialist  |
| Isabella Robbins     | Patient / Carer Member  | Patient/Carer Member       |
| Jeremy Rees          | Honorary Consultant Neurologist Royal Marsden Hospital, Royal National Orthopaedic Hospital and Mount Vernon Cancer Centre                  | Neurologist                |
| Sara Erridge         | Consultant Clinical Oncologist and Honorary Senior Lecturer, Edinburgh Cancer Centre, Western General Hospital                              | Clinical Oncologist        |
| Sara Robson          | Specialist Allied Health Professional brain and central nervous system tumour rehabilitation, The Christie NHS Foundation Trust, Manchester | Allied Health Professional |
| Sarah Jefferies      | Consultant Clinical Oncologist at Addenbrooke's Hospital, Cambridge   | Clinical Oncologist        |
| Sebastian Brandner   | Professor and Chair of Neuropathology and Honorary Consultant Neuropathologist, UCL Institute of Neurology                                  | Histopathologist           |
| Stuart Smith         | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals  | Neuro-oncology surgeon     |
| Zoe Faulkner         | Patient / Carer Member  | Patient/Carer Member       |

# Register of declarations of interest

The effective management of conflicts of interests is an essential element in the development of the guidance and advice that NICE publishes. This document records declarations made at any stage in the guideline development process, from recruitment to the final Committee meeting. In April 2018 the NICE policy on Declarations of Interest changed, however as the Committee met and the guideline was developed before that policy was implemented the Committee members' declarations of interest have been recorded according to the previous policy's requirements.

| Name       | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|------------|--|--|---------------------------------------|-------------------------|
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Member of the trial steering committee for the StatRoc study (A Feasibility Study of Adjuvant Statin Therapy in the Prevention of Post-Operative Recurrence of Oesophageal Adenocarcinoma). Funded by NIHR. No involvement in designing trial protocol (Declared at Recruitment) | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Member of the trial management group for the ART DECO trial (randomised Phase III trial of dose-escalation in laryngeal /hypopharyngeal cancer). Funded by CRUK. (Declared at Recruitment)   | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Local principle investigator for DeteQT (QoL instruments in thyroid cancer). Funded by Macmillan / Coventry. Trial now finished recruiting   | Non-Personal, Financial, Non-specific | Declare and participate |

| Name       | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|------------|--|--|---------------------------------------|-------------------------|
|            |  | but still being written up. (Declared at recruitment)  |                                       |                         |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Local principle investigator for Head and Neck 5000. Funded by University Hospital Bristol. Trial now finished recruiting but still being written up. (Declared at recruitment)  | Non-Personal, Financial, Non-specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Principle investigator for IoN (I-131 in low risk thyroid cancer). Funded by UCL/CRUK. (Declared at recruitment)   | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Principle investigator for SCORAD-III (radiotherapy dose for spinal cord compression). Funded by UCL / CRUK. (Declared at recruitment)   | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Principle investigator for ESPAC-4 (EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers). Funded by CRUK. Trial now finished recruiting but still being written up | Non-Personal, Financial, Non-Specific | Declare and participate |

| Name       | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|------------|--|---|---------------------------------------|-------------------------|
|            |  | (Declared at recruitment)   |                                       |                         |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Principle investigator for ST03 trial (A Randomised Phase II/III trial of Peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in selected centres) MRI and PET/CT Sub-studies). Funded by CRUK (Declared at recruitment) | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Principle investigator for GO2 trial (Alternative chemotherapy for frail or elderly patients with advanced gastric or oesophageal cancer). Funded by CRUK (Declared at recruitment)   | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Involved with PLATFORM (Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy) trial. Funded by MedImmune, Inc.   | Non-Personal, Financial, Non-Specific | Declare and participate |



| Name       | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|------------|--|---|---------------------------------------|-------------------------|
|            |  | And Merrimack Pharmaceuticals<br>(Declared at recruitment)  |                                       |                         |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Co-investigator for the DARS trial (dysphagia optimized intensity modulated radiotherapy (do-IMRT) versus standard IMRT in head and neck cancer). Grant application submitted to CRUK – trial has not yet got ethics approval. Involved in designing the trial protocol.<br>(Declared at recruitment) | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Radiotherapy advisor to the De-escalate study (comparing different therapies in combination with RT in HPV+ oropharyngeal cancer. Funded by CRUK. Designed trial protocol.<br>(Declared at recruitment)   | Non-Personal, Financial, Non-Specific | Declare and participate |
| Tom Roques | Consultant clinical oncologist, Norfolk and Norwich University Hospital. | Local principle investigator for a head and neck cancer trial MK-3475 (pembrolizumab) Protocol 412: Study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects   | Non-Personal, Financial, Non-Specific | Declare and participate |

| Name              | Job title, organisation                               | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|-------------------|---|---|---------------------------------------|-------------------------|
|                   |   | with locally advanced head and neck squamous cell carcinoma. Funded by Merck.<br>(Declared 24.10.17)  |                                       |                         |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | Acted as an advisor to Advanced Accelerators in France in March 15. No fee received. Gave advice on whether or not injection of radiolabelled nanoparticles for treatment of glioblastoma was a good idea. May be contacted again in future. This technology is at the stage of feasibility studies – not part of clinical practice.<br>(Declared at recruitment) | Personal, Non-Financial, Non-Specific | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | Has been asked by the Brain Tumour Charity to give a talk at their summer 16 meeting on current research in brain tumours.<br>(Declared at recruitment)   | Personal, Non-Financial, Non-Specific | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | Local investigator on the DCVax study (to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed glioblastoma for whom surgery is indicated). Funded by Northwest Biotherapeutics.   | Non-Personal, Financial, Specific     | Declare and participate |

| Name              | Job title, organisation                               | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                  | Decision taken          |
|-------------------|---|--|-----------------------------------|-------------------------|
|                   |   | Responsible for administering the trial locally – no involvement in designing trial protocol.<br>(Declared at recruitment)   |                                   |                         |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | Local investigator on a Phase I trial of olaparib (AZD2281), an oral PARP Inhibitor, in combination with extended low dose oral temozolomide in patients with relapsed glioblastoma. Funded by CRUK. Responsible for administering the trial locally – no involvement in designing trial protocol.<br>(Declared at recruitment)            | Non-Personal, Financial, Specific | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | Chief investigator on the IDEB trial (A Phase I Study of Intraparenchymal Therapy with Irinotecan Hydrochloride Drug-Eluting Beads (CM-BC2) as an Adjunct Therapy to Best Standard of Care in Patients with Recurrent, Surgically Resectable Glioblastoma Multiforme). Funded by BTG International Inc. Study finished in October 2015 but | Non-Personal, Financial, Specific | Declare and participate |

| Name              | Job title, organisation                               | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                  | Decision taken          |
|-------------------|---|--|-----------------------------------|-------------------------|
|                   |   | <p>results not yet published. Responsible for administering the trial locally – no involvement in designing trial protocol. (Declared at recruitment)</p>  |                                   |                         |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | <p>Co-investigator for the HIPPO trial (Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases). Funded by University College London. Involvement is only to contribute patients to the trial (Declared at recruitment)</p> | Non-Personal, Financial, Specific | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | <p>Chair of the DVLA medical panel. Involves making decisions about who can have a license to drive with neurological medical conditions. (Declared at recruitment)</p>  | Personal, Financial, Non-Specific | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | <p>Named in a petition to the House of Commons about early diagnosis of brain tumours. Attended a petition select committee and answered questions about brain tumours. (Declared at recruitment)</p>  | Personal, Non-Financial, Specific | Declare and participate |

| Name              | Job title, organisation                               | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|-------------------|---|--|---------------------------------------|-------------------------|
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | BMJ Open Bennett, S.R., et al., Investigating the impact of headaches on the quality of life of patients with glioblastoma multiforme: a qualitative study. BMJ Open, 2016. 6(11). (Declared 25.01.2017)   | Personal, Non-Financial, Specific     | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | Further advice to Petitions Committee on Brain Tumour research in UK (Declared 25.01.2017)   | Personal, Non-Financial, Specific     | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | BASO/NCRI meeting Liverpool November 2016 Presentation and interview on local control of brain metastases (Declared 25.01.2017)  | Personal, Non-Financial, Specific     | Declare and participate |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | PI in the STING study 'Study of Immunotherapy in Newly diagnosed Glioblastoma: A Phase three randomised double blind controlled trial of ICT-107 with maintenance Temozolomide (TMZ) following resection and concomitant TMZ chemoradiotherapy'<br><br>The study is commercially sponsored by Immunocellular | Non-Personal, Financial, Non-Specific | Declare and participate |

| Name              | Job title, organisation                               | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|-------------------|---|---|---------------------------------------|-------------------------|
|                   |   | Therapeutics LA/US Clinical Trials No: NCT 02546102 (Declared 25.01.2017 & 28.04.2017)  |                                       |                         |
| Garth Cruickshank | Professor of Neurosurgery and Consultant Neurosurgeon | <p>Undertake private practice for the treatment of gliomas, meningiomas and cerebral metastases.</p> <p>Interventions delivered privately include cranial procedures such as OPCS A.02X for HRG C71. In addition I also provide surgical treatment for trigeminal neuralgia, hemifacial spasm, hydrocephalus and other skull base procedures. They are the same as those delivered by the NHS.</p> <p>(Declared 28.02.18)</p> | Personal, Financial, Specific         | Declare and participate |
| Eileen Andrews    | Macmillan Neuro Oncology Clinical Nurse Specialist    | <p>In December 2016 ran an information day for people with brain tumours at Queen Square with the Brain Tumour Charity. Involvement included a speech and organising speakers. No financial reimbursement.</p> <p>(Declared 24.10.17)</p>   | Personal, Non-Financial, Non-Specific | Declare and participate |

| Name               | Job title, organisation     | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|--------------------|-----------------------------|---|---------------------------------------|-------------------------|
| Sebastian Brandner | Professor of Neuropathology | I am the lead of a large molecular pathology testing service for the NHS. This service generates income which partly funds technical staff in my department. There is no personal financial gain from this service. Tests used are ones that are available to the NHS (Declared at recruitment) | Non-Personal, Financial, Non-Specific | Declare and participate |
| Sebastian Brandner | Professor of Neuropathology | I occasionally act (once or twice per year) as expert witness in medicolegal cases, requiring expertise to assess adequate treatment and diagnosis. Fees received go into a UCL charitable account which is used to support professional and academic activities (Declared at recruitment)      | Non-Personal, Financial, Non-Specific | Declare and participate |
| Sebastian Brandner | Professor of Neuropathology | Provide support for brain tumour charities (the Brain Tumour Charity and Brain Tumour Research) at events etc. (Declared at recruitment)  | Personal, Non-Financial, Non-Specific | Declare and participate |
| Sebastian Brandner | Professor of Neuropathology | I am involved (providing diagnosis of pathology specimens and second opinions) in clinical trials on brain tumours being  | Personal, Non-Financial, Non-Specific | Declare and participate |

| Name               | Job title, organisation     | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|--------------------|-----------------------------|---|---------------------------------------|-------------------------|
|                    |                             | run by the Trust. No direct involvement in any trials.<br>(Declared 17.11.2016)   |                                       |                         |
| Sebastian Brandner | Professor of Neuropathology | Publication of review in Journal of Neurology "Neurological Update: gliomas and other primary brain tumours in adults"<br>(Declared 24-25.10.2017)  | Personal, Non-Financial, Non-Specific | Declare and participate |
| Helen Bulbeck      | Lay member                  | Honorarium for attending meeting on behalf of the Brain Cancer community to explore ocular side effects in a drug Pharma- abbice. It's not a drug being discussed.<br>(Declared at recruitment) | Non-specific, personal financial      | Declare and participate |
| Helen Bulbeck      | Patient / carer member      | Asked by Springer Publishing to write a chapter for a book on brain tumours for neuro oncology nursing. This project is expected to last around 18 months.<br>(Declared at recruitment)         | Personal, Financial, Non-Specific     | Declare and participate |
| Helen Bulbeck      | Patient / carer member      | Funding from Abbvie to attend a patient focused group in Germany – travel and accommodation paid.<br>(Declared at recruitment)  | Personal, Financial, Non-Specific     | Declare and participate |



| Name           | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|----------------|--------------------------------|--|---------------------------------------|-------------------------|
| Helen Bulbeck  | Patient / carer member         | Founder, director and paid employee of brainstrust (a brain cancer charity).<br>(Declared at recruitment)  | Personal, Financial, Non-specific     | Declare and participate |
| Alison Cameron | Consultant clinical oncologist | Elekta has been invoiced by UH Bristol for the Bristol Gamma knife team to be interviewed (including myself) for a video that Elekta were making. Elekta has requested that I do a presentation at Pre-ESTRO meeting in Vienna in May 2017. Elekta will pay travel/accommodation if needed.<br>(Declared 09.03.2017) | Non-Personal, Financial, Specific     | Declare and participate |
| Alison Cameron | Consultant clinical oncologist | Giving talk at International Stereotactic Radiosurgery Society meeting in May 2017. This talk relates to SRS platforms.<br>(Declared 09.03.2017)   | Non-Personal, Non-Financial, Specific | Declare and participate |
| Alison Cameron | Consultant clinical oncologist | Accepted invitation to attend 2 weeks training in proton therapy at University of Pennsylvania in February 2018. Costs of trip to be funded by Proton Partners International.<br>(Declared 25-26.09.2017)  | Personal, Financial, Non-Specific     | Declare and participate |

| Name           | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|----------------|--------------------------------|--|---------------------------------------|-------------------------|
| Alison Cameron | Consultant clinical oncologist | Local principal investigator for BR14 trial (grade 3 non-codeleted glioma adjuvant radiotherapy with randomisations for concomitant and adjuvant temozolamide). Closed to recruitment, in follow up.<br><br>(Declared 25-26.09.2017) | Personal, Non-Financial, Specific     | Declare and participate |
| Alison Cameron | Consultant clinical oncologist | Local principal investigator for EORTC 1320 trial (grade 2/3 meningioma-palliative investigators choice chemotherapy versus trabectedin). Closed to recruitment, in follow up.<br><br>(Declared 25-26.09.2017)                       | Personal, Non-Financial, Specific     | Declare and participate |
| Alison Cameron | Consultant clinical oncologist | Local principal investigator for ROAM study (grade 2 meningioma - observation versus adjuvant radiotherapy). Open to recruitment.<br><br>(Declared 25-26.09.2017)  | Personal, Non-Financial, Specific     | Declare and participate |
| Alison Cameron | Consultant clinical oncologist | Local principal investigator for Brightlight study (impact of cancer on TYA patients). Closed to   | Personal, non-Financial, Non-Specific | Declare and participate |

| Name                 | Job title, organisation               | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken   |
|----------------------|---------------------------------------|--|---------------------------------------|--|
|                      |                                       | recruitment, in follow up.<br><br>(Declared 25-26.09.2017)   |                                       |  |
| Alison Cameron       | Consultant clinical oncologist        | Undertake private practice for acoustic neuroma, meningioma and craniopharngioma.<br><br>Interventions delivered privately include SRS, hypofractionated SRT and fractionated SRT and are the same as those delivered by the NHS.<br>(Declared 23.01.18) | Personal, Financial, Specific         | Declare and participate as interventions delivered privately are the same as those delivered by the NHS. |
| Catherine Derbyshire | Consultant clinical neuropsychologist | Received a fee from Hull University in May 16 for giving a lecture on mindfulness based cognitive behavioral therapy.<br>(Declared at recruitment)   | Personal, Financial, Non-Specific     | Declare and participate  |
| Catherine Derbyshire | Consultant clinical neuropsychologist | Undertaken a qualitative study of people's experiences of taking part in MBCT for cancer. Currently writing up and hoping to publish in 2017. No industry funding for study<br>(Declared at recruitment)   | Personal, Non-Financial, Non-Specific | Declare and participate  |
| Catherine Derbyshire | Consultant clinical neuropsychologist | On the steering group for a Macmillan project on service re-design/improvement for brain tumours (focused on the role  | Personal, Non-Financial, Non-Specific | Declare and participate  |

| Name                 | Job title, organisation               | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|----------------------|---------------------------------------|---|---------------------------------------|-------------------------|
|                      |                                       | of the CNS and improving communication with patients.<br>(Declared at recruitment)  |                                       |                         |
| Catherine Derbyshire | Consultant clinical neuropsychologist | In a video discussing role of neuropsychology in rehab team for brain tumors. This will be used by Macmillan project which is being completed with our team.<br>(Declared 17.11 2017)   | Personal, Non-Financial, Non-Specific | Declare and participate |
| Catherine Derbyshire | Consultant clinical neuropsychologist | Will be reducing my hours at current trust (Hull and East Yorkshire) to take up a new post with Leeds teaching hospitals trust as lead Neuropsychologist. Job split will be 0.4 WTE at Hull & East 0.6 WTE at Leeds teaching hospitals<br>(Declared 17.11.2016) | Personal, Financial, Non-Specific     | Declare and participate |
| Sara Erridge         | Consultant clinical oncologist        | My department performs some training for Brainlab on stereotactic radiotherapy for UK/Irish centres. Currently this is provided gratis, but in the future the department may receive a payment but I will not personally benefit.<br>(Declared at recruitment)  | Non-Personal, Financial, Specific     | Declare and participate |

| <b>Name</b>  | <b>Job title, organisation</b> | <b>Declarations of Interest, date declared (recruitment / committee meeting)</b>   | <b>Type of interest</b>             | <b>Decision taken</b>   |
|--------------|--------------------------------|--|-------------------------------------|-------------------------|
| Sara Erridge | Consultant clinical oncologist | Co-author of radiotherapy protocol for EORTC 22081 (CoDel) – Phase III Grade II glioma. Radiation therapy and concurrent plus adjuvant Temozolimus (CCI779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open label, Phase II study (Declared at recruitment) | Non-Personal, Financial, Specific   | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Co-author of radiotherapy protocol for EORTC 22082 (Torisel) – Phase II glioblastoma (Declared at recruitment)   | Non-Personal, Financial, Specific   | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Radiotherapy lead for CENTRIC – EORTC 26072-22071 trial – Phase III in glioblastoma (Declared at recruitment)  | Non-Personal, Financial, Specific   | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Radiotherapy lead for EORTC 26052/22053 - RTOG 0525 – Phase III in glioblastoma (European Radiotherapy lead and the UK chief investigator.) Phase III Trial comparing Conventional   | Non-Personal, - Financial, Specific | Declare and participate |

| Name         | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                  | Decision taken          |
|--------------|--------------------------------|--|-----------------------------------|-------------------------|
|              |                                | Adjuvant Temozolomide with Dose Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma (Declared at recruitment)   |                                   |                         |
| Sara Erridge | Consultant clinical oncologist | UK chief investigator for BR14 (CATNON) - A Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in 1p/19q intact anaplastic glioma. The CATNON Intergroup Trial. (Declared at recruitment)  | Non-Personal, Financial, Specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | UK chief investigator for EORTC 26091 (Taverec) – Randomised trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. Trial is closed to recruitment but has not yet published. Was responsible for the regulatory running of the trial. (Declared at recruitment) | Non-Personal, Financial, Specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for EORTC 1320 – Phase II for meningioma (Declared at recruitment)  | Non-Personal, Financial, Specific | Declare and participate |

| <b>Name</b>  | <b>Job title, organisation</b> | <b>Declarations of Interest, date declared (recruitment / committee meeting)</b>   | <b>Type of interest</b>           | <b>Decision taken</b>   |
|--------------|--------------------------------|--|-----------------------------------|-------------------------|
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for ACT IV (commercial) – Phase III glioblastoma (Declared at recruitment)  | Non-Personal, Financial, Specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for OPARATIC Phase I glioblastoma (Declared at recruitment)   | Non-Personal, Financial, specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for EORTC 26101 Phase III glioblastoma Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma (Declared at recruitment) | Non-Personal, Financial, Specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for M13-813 (commercial) Phase III glioblastoma (Declared at recruitment)   | Non-Personal, Financial, Specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for BR13 – Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas with stratification for genetic 1p loss: a phase III study (Declared at recruitment)  | Non-Personal, Financial, Specific | Declare and participate |

| <b>Name</b>  | <b>Job title, organisation</b> | <b>Declarations of Interest, date declared (recruitment / committee meeting)</b>  | <b>Type of interest</b>               | <b>Decision taken</b>   |
|--------------|--------------------------------|---|---------------------------------------|-------------------------|
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for BR12- (also on TMG) Temozolomide vs PCV chemotherapy in the treatment of recurrent malignant glioma (Declared at recruitment)  | Non-Personal, Financial, Specific     | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Local principal investigator for 22042: Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a Phase-II and observation study (Declared at recruitment)   | Non-Personal, Financial, Specific     | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Centre are hosting the National Scottish Neuro-oncology Network Annual meeting. Has drug company sponsorship from Varian and Brainlab. Responsible for developing programme for meeting. Has not negotiated sponsorship – although did approach some companies about being potential sponsors (Declared at recruitment) | Non-Personal, Financial, Non-Specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Signatory on a neuro-oncology fund for Edinburgh Cancer Centre. Used to provide departmental  | Non-Personal, Financial, Non-Specific | Declare and participate |



| Name         | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|--------------|--------------------------------|--|---------------------------------------|-------------------------|
|              |                                | education and training. No industry contributions to the fund.<br>(Declared at recruitment)  |                                       |                         |
| Sara Erridge | Consultant clinical oncologist | Author of paper considered in evidence reviews: Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (Lancet, 2017)<br>(Declared at recruitment) | Personal, Non-Financial, Specific     | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Author of paper not considered in evidence reviews: Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG (Neuro Oncology, 2017)<br>(Declared 24.10.17)  | Personal, Non-Financial, Non-Specific | Declare and participate |
| Sara Erridge | Consultant clinical oncologist | Author of paper not considered in evidence reviews: Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma (Journal of  | Personal, Non-Financial, Non-Specific | Declare and participate |

| Name            | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|-----------------|--------------------------------|--|---------------------------------------|-------------------------|
|                 |                                | Neurooncology, 2018)<br>(Declared 05.03.18)  |                                       |                         |
| Sara Erridge    | Consultant clinical oncologist | Author of paper not considered in evidence reviews:<br>Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG, (Neuro Oncol. 2017)<br>(Declared 05.03.18) | Personal, Non-Financial, Non-Specific | Declare and participate |
| Zoe Faulkner    | Lay member                     | Received travel expenses from the Brain Tumour Charity in May 16 for giving a presentation on carers experiences.<br>(Declared at recruitment)   | Personal, Financial, Non-Specific     | Declare and participate |
| Zoe Faulkner    | Lay member                     | Reviewed a video about explaining adult brain tumours to children, for the Brain Tumour Charity. No fees received.<br>(Declared at recruitment)  | Personal, Non-Financial, Non-Specific | Declare and participate |
| Sarah Jefferies | Consultant clinical oncologist | Received a fee and reimbursement of travel expenses for teaching on CNS tumours at 5 day training course in April 2016 from European Society for Radiotherapy and Oncology.<br>(Declared at recruitment)   | Personal, Financial, Non-Specific     | Declare and participate |

| <b>Name</b>     | <b>Job title, organisation</b> | <b>Declarations of Interest, date declared (recruitment / committee meeting)</b>  | <b>Type of interest</b>               | <b>Decision taken</b>  |
|-----------------|--------------------------------|---|---------------------------------------|--|
| Sarah Jefferies | Consultant clinical oncologist | Received a fee and reimbursement of travel expenses for teaching on CNS tumours at London MSc programme from Royal College of Radiologists. (Declared at recruitment)   | Personal, Financial, Non-Specific     | Declare and participate  |
| Sarah Jefferies | Consultant clinical oncologist | Has been an invited speaker at Brain Tumour Charity events – no fee received. (Declared at recruitment)   | Personal, Non-Financial, Non-Specific | Declare and participate  |
| Sarah Jefferies | Consultant clinical oncologist | Co-applicant (applied for funding, involved in designing trial protocol) for the GALA-5 Trial: An evaluation of the tolerability and feasibility of combining 5-ALA with Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastomas (CRUK) (Declared at recruitment) | Non-Personal, Financial, Specific     | Declare and participate after discussion with NICE at recruitment about exact role in trial. |
| Sarah Jefferies | Consultant clinical oncologist | Co-applicant (applied for funding, involved in designing trial protocol) for the Real time clinical imaging of tumour metabolism using hyperpolarized <sup>13</sup> C magnetic resonance spectroscopy (Welcome Trust) (Declared at recruitment)   | Non-Personal, Financial, Specific     | Declare and participate  |

| <b>Name</b>     | <b>Job title, organisation</b> | <b>Declarations of Interest, date declared (recruitment / committee meeting)</b>   | <b>Type of interest</b>               | <b>Decision taken</b>   |
|-----------------|--------------------------------|--|---------------------------------------|-------------------------|
| Sarah Jefferies | Consultant clinical oncologist | Co-applicant (applied for funding, involved in designing trial protocol) for the CAMBT1: Randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy (CRUK) (Declared at recruitment) | Non-Personal, Financial, Specific     | Declare and participate |
| Sarah Jefferies | Consultant clinical oncologist | Local Principle Investigator for the ION STUDY – Randomised non-blind non-inferiority phase II/III multicentre trial assessing the role of low dose radioiodine versus no iodine for early stage thyroid cancer. Funded by CRUK (Declared at recruitment)  | Non-Personal, Financial, Non-Specific | Declare and participate |
| Sarah Jefferies | Consultant clinical oncologist | Local principle investigator for OPARATIC – Phase I trial of olaparib (AZD2281), an oral PARP Inhibitor, in combination with extended low dose oral temozolomide in patients with relapsed glioblastoma. Funded by CRUK  | Non-Personal, Financial, Specific     | Declare and participate |

| Name            | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|-----------------|--------------------------------|---|---------------------------------------|-------------------------|
|                 |                                | (Declared at recruitment)   |                                       |                         |
| Sarah Jefferies | Consultant clinical oncologist | National Lead Investigator for EORTC Study 26101 (did ethics approval to get trial into UK portfolio) – Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma. Funded by EORTC. (Declared at recruitment)                      | Non-Personal, Financial, Specific     | Declare and participate |
| Sarah Jefferies | Consultant clinical oncologist | Is a signatory of the William Brown Trust (part of Addenbrooks Charitable Trust). Used to fund local education and support events/meetings for staff. (Declared at recruitment)   | Non-Personal, Financial, Non-Specific | Declare and participate |
| Sarah Jefferies | Consultant clinical oncologist | Co-author of Fast imaging employing steady-state acquisition (FIESTA) MRI to investigate cerebrospinal fluid (CSF) within dural reflections of posterior fossa cranial nerves. Noble DJ, Scoffings D, Ajithkumar T, Williams MV, Jefferies SJ. Br J Radiol. 2016 Nov;89(1067) (Declared 17.11.2016) | Personal, Non-Financial, Specific     | Declare and participate |

| Name            | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|-----------------|--------------------------------|--|---------------------------------------|-------------------------|
| Sarah Jefferies | Consultant clinical oncologist | Co-author on A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Muropeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW. Clin Cancer Res. 2016 Oct 1;22(19):4776-4785. (Declared 17.11.2016) | Personal, Non-Financial, Non-Specific | Declare and participate |
| Sarah Jefferies | Consultant clinical oncologist | Co-author on Evolving treatment options for melanoma brain metastases. Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S. Lancet Oncol. 2015 Oct;16(13):e486-97 (Declared 17.11.2016)   | Personal, Non-Financial, Non-Specific | Declare and participate |
| Sarah Jefferies | Consultant clinical oncologist | Attending a sponsored educational meeting in the 16.10.2017 – Stereotactic radiotherapy in the skull base (London  | Personal, Financial, Non-Specific     | Declare and participate |

| Name            | Job title, organisation        | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                  | Decision taken   |
|-----------------|--------------------------------|--|-----------------------------------|--|
|                 |                                | – Gammaknife centre)<br>(Declared 24-25.10.2017)   |                                   |  |
| Sarah Jefferies | Consultant clinical oncologist | Genesis care are providing a private radiotherapy facility in Newmarket near Cambridge. I will utilise this facility if it proceeds to treat private patients.<br>(Declared 24-25.10.2017)   | Personal, Financial, Non-Specific | Declare and participate  |
| Sarah Jefferies | Consultant clinical oncologist | Planning to put in research grant application on non-IDH mutated low-grade glioma, which is similar research recommendations.<br>(Declared 24-25.10.2017)  | Non-Personal, Financial, Specific | Declare and participate – research recommendations were selected through blind vote and therefore this was judged unlikely to be a conflict. |
| Sarah Jefferies | Consultant clinical oncologist | Undertake private practice for patients with CNS tumours and thyroid malignancy. Up until October 2017 undertook private practice for patients with a diagnosis of head and neck cancer.<br><br>Interventions delivered privately include radiotherapy, chemotherapy and radioiodine, and are the same as those delivered by the NHS.<br>(Declared 23.01.18) | Personal, Financial, Specific     | Declare and participate as interventions delivered privately are the same as those delivered by the NHS.                                     |
| Sarah Jefferies | Consultant clinical oncologist | Has invested in Genesis Care through a company co-owned with her   | Personal, Financial, Non-specific | Declare and participate as interventions delivered privately are   |

| Name         | Job title, organisation      | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken                          |
|--------------|------------------------------|---|---------------------------------------|---|
|              |                              | <p>husband. Genesis Care are building a private radiotherapy and chemotherapy facility which Sarah Jefferies will utilise.</p> <p>The facility is for all types of cancer and will be providing the same types radiotherapy and chemotherapy treatment currently offered for all patients treated at the NHS hospital where she works.</p> <p>(Declared 10.04.18)</p> |                                       | the same as those delivered by the NHS. |
| Ingela Oberg | MacMillan neuro-oncology CNS | Lead Nurse for EANO – they pay expenses to attend their conference and meetings<br>(Declared at recruitment)  | Personal, Financial, Non-Specific     | Declare and participate                 |
| Ingela Oberg | MacMillan neuro-oncology CNS | I have been asked by Springer Publishing to write a book on brain tumours for neuro oncology nursing. This project is expected to last around 18 months.<br>(Declared 17.11.2016)   | Personal, Financial, Non-Specific     | Declare and participate                 |
| Jeremy Rees  | Consultant Neurologist       | Attended a workshop in June 16 organised by Zambon SpA on the use of a new drug safinamide in Parkinson's disease. No fee received.<br>(Declared at recruitment)  | Personal, Non-Financial, Non-Specific | Declare and participate                 |



| Name        | Job title, organisation | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|-------------|-------------------------|---|---------------------------------------|-------------------------|
| Jeremy Rees | Consultant Neurologist  | Principal Clinical Investigator for the Epigenome of neural stem cells and high grade gliomas lab-based study. Funded by Brain Tumour Research Charity. Role is to recruit patients coming through for surgery. Not involved in designing trial protocol. (Declared at recruitment) | Non-Personal, Financial, Specific     | Declare and participate |
| Jeremy Rees | Consultant Neurologist  | Advisory role on a study investigating improving outcome in Low-Grade Glioma using advanced pre- and intra-operative MRI. Funded by Comprehensive Biomedical Research Centre. (Declared at recruitment)   | Personal, Non-Financial, Specific     | Declare and participate |
| Jeremy Rees | Consultant Neurologist  | Will be recruiting patients for VIBES (Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumours). Funded by PRA Health Sciences. Not involved in designing trial protocol. (Declared at recruitment)   | Personal, Non-Financial, Non-Specific | Declare and participate |
| Jeremy Rees | Consultant Neurologist  | Co-Author on a paper published in Annals of Oncology on Neurotoxicity of  | Personal, Non-Financial, Non-Specific | Declare and participate |

| Name        | Job title, organisation | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                  | Decision taken  |
|-------------|-------------------------|---|-----------------------------------|---|
|             |                         | immune check point inhibitors and paper in practical Neurology on Acute Demyelination following radiotherapy in 2 patients with Gliomas.<br>(Declared 17.11.2016)   |                                   |   |
| Jeremy Rees | Consultant Neurologist  | Co-author on a paper published in Lancet Oncology on RT vs TMZ in low-grade glioma – “Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study”<br>(Declared 25.01.2017) | Personal, Non-Financial, Specific | Declare and participate   |
| Jeremy Rees | Consultant Neurologist  | Advised father-in-law to buy shares in NovoCure, a company making Tumour treating Field technology (relevant to the treatment of glioma and brain metastases)<br><br>(Declared 26.10.17)  | Personal, Financial, Specific     | Withdraw from all discussion of the technology, and any discussions of technology that TTF might compete with (specifically all treatment for glioma and metastases). Consequently no recommendation on these topics subsequent to the date of the declaration (26.10.17) will be conflicted. |
| Jeremy Rees | Consultant Neurologist  | Undertake private practice in both general neurology and neuro-oncology. Interventions delivered privately  | Personal, Financial, Specific     | Declare and participate as interventions delivered privately are the same as those delivered by the NHS.  |

| Name             | Job title, organisation | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|------------------|-------------------------|--|---------------------------------------|-------------------------|
|                  |                         | are the same as those delivered by the NHS.<br><br>(Declared 23.01.18)   |                                       |                         |
| Isabella Robbins | Patient / carer member  | Reimbursement of travel expenses to attend East Midlands Brain and CNS ECAG.<br>(Declared at recruitment)  | Personal, Financial, Non-Specific     | Declare and participate |
| Sara Robson      | Occupational Therapist  | Has given talks and support at local brain tumour support group (organised by the Brain Tumour Charity) and also at the Brains Trust. No fees received.<br>(Declared at recruitment)                                 | Personal, Non-Financial, Non-Specific | Declare and participate |
| Sara Robson      | Occupational Therapist  | Attended an information gathering exercise for the NIHR – looking at funding research into the use of exercise to combat fatigue in people with primary brain tumours. No fee received.<br>(Declared at recruitment) | Personal, Non-Financial, Non-Specific | Declare and participate |
| Sara Robson      | Occupational Therapist  | Recent completion and reports submitted from 2 projects funded by Macmillan innovation grants. Health and Wellbeing for people with Primary brain tumours<br>Education for Professionals about                       | Personal, Financial, Non-Specific     | Declare and participate |

| Name         | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|--------------|--|---|---------------------------------------|-------------------------|
|              |  | treating people with brain metastases. Both involve video/presentations now available on Youtube & reports submitted to Macmillan- no financial gain. (Declared 17.11.2016)   |                                       |                         |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Local co-ordinator and investigator (patient recruitment and following protocol) for the ASPECT Trial (A Controlled, Randomised, Parallel Group, Multicentre Study of the Efficacy and Safety of Herpes Simplex Virus-Thymidine Kinase Gene therapy (CereproTM) with Subsequent Ganciclovir, for the Treatment of Patients with Operable High Grade Glioma). Funded by Ark Therapeutics Limited (Declared at recruitment) | Non-Personal, Financial, Non-Specific | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Local PI for brain-TV study (investigating a modified form of Doppler ultrasound to measure intracranial pressure in trauma patients). Funded by Leicester University (who received an  | Non-Personal, Financial, Non-Specific | Declare and participate |

| Name         | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|--------------|--|--|---------------------------------------|-------------------------|
|              |  | unrestricted grant from Hitachi)<br>(Declared at recruitment)  |                                       |                         |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Local PI for Rescue-ASDH trial (Randomised Evaluation of Surgery with Craniectomy for patients Undergoing Evacuation of Acute Subdural Haematoma). Funded by NIHR (Declared at recruitment)  | Non-Personal, Financial, Non-Specific | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Local PI for Dex-CSDH trial (A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic chronic subdural haematoma). Funded by NIHR. (Declared at recruitment) | Non-Personal, Financial, Non-Specific | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Local PI for ROAM trial (Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial). Funded by NETSCC (Declared at recruitment)  | Non-Personal, Financial, Specific     | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham                      | Recruited patients for the BASICS trial (The British Antibiotic and Silver Impregnated Catheters for ventriculoperitoneal  | Personal, Non-Financial, Non-Specific | Declare and participate |

| Name         | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                          | Decision taken          |
|--------------|--|--|---|-------------------------|
|              | University Hospitals   | Shunts multi-centre randomised controlled trial). Funded by NIHR (Declared at recruitment)   |   |                         |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Recruited patients for RESCUE ICP (Randomised Evaluation of Surgery with Craniectomy for Uncontrollable Elevation of ICP). Funded by Academy of Medical Sciences (UK); The Health Foundation (UK) MRC managed by NIHR on behalf of the MRC-NIHR partnership (UK) (Declared at recruitment) | Non-Personal, Non-Financial, Non-Specific | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Local investigator for the PRAM-GBM study looking at imaging to predict sites of tumour progression following surgery for glioblastoma. Funded by CRUK. (Declared at recruitment)  | Non-Personal, Financial, Specific         | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Post at University of Nottingham (along with other posts) is funded by a charitable donation from a private individual. (Declared at recruitment)  | Personal, Financial, Non-Specific         | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham                      | Has developed patient information leaflets and given talks about brain cancer and brain  | Personal, Non-Financial, Non-Specific     | Declare and participate |

| Name         | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                  | Decision taken          |
|--------------|--|---|-----------------------------------|-------------------------|
|              | University Hospitals   | cancer research. No fee received. (Declared at recruitment)   |                                   |                         |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | In receipt of a grant from the Brain Tumour Charity to do molecular laboratory based research. (Declared at recruitment)  | Personal, Financial, Non-Specific | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Research project with Inovitro (research arm of Optune) on potential treatment for glioblastoma – no financial support, loan of research equipment and technological advice. (Declared 28.04.2017)              | Non-Personal, Financial, Specific | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Oral presentations at British Neuro-Oncology Society Meeting<br>1) Tumour Heterogeneity<br>2) Drug Delivery to Brain Tumours<br>3) Use of Optune on paediatric brain tumour cell lines<br>(Declared 17.07.2017) | Personal, Non-Financial, Specific | Declare and participate |
| Stuart Smith | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Poster Presentations at British Neuro-Oncology Society Meeting<br>1) Tumour Heterogeneity<br>2) Re-purposing DBS for brain tumour treatment   | Personal, Non-Financial, Specific | Declare and participate |

| Name          | Job title, organisation  | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|---------------|--|---|---------------------------------------|-------------------------|
|               |  | 3) Tumour metabolism (Declared 17.07.2017)  |                                       |                         |
| Stuart Smith  | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Published paper in Biomed. Res. Int 2017 (4) 915370-13: "MicroRNA regulation of Glycolytic Metabolism in GBM". (Declared 24-25.10.2017)   | Personal, Non-Financial, Non-Specific | Declare and participate |
| Stuart Smith  | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Author of paper not considered in evidence reviews: The invasive region of Glioblastoma defined by 5ALA guided surgery has an altered cancer stem cell marker profile compared to central tumour Int J Mol Sci 2017 (Declared 05.03.18) | Personal, Non-Financial, Non-Specific | Declare and participate |
| Stuart Smith  | Clinical Associate Professor Neurosurgery, Nottingham University Hospitals | Author of paper not considered in evidence reviews: The Molecular and Phenotypic Basis of the Glioma Invasive Perivascular Niche Int J Mol Sci 2017 (Declared 05.03.18)   | Personal, Non-Financial, Non-Specific | Declare and participate |
| David Summers | Neuroradiologist   | Received travel expenses from Biogen to attend a workshop on imaging in multiple sclerosis in December 2015 (Declared at recruitment)   | Personal, Financial, Non-Specific     | Declare and participate |



| Name          | Job title, organisation | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                  | Decision taken          |
|---------------|-------------------------|---|-----------------------------------|-------------------------|
| David Summers | Neuroradiologist        | As part of a new hospital build, department will soon be procuring new MRI scanners. As the radiologist involved it is likely that I will be attending sites in the UK and Europe to review these scanners on site visits, the travel and subsistence costs of which will be met by the scanner manufacturer concerned. (Declared at recruitment)   | Personal, Financial, Non-Specific | Declare and participate |
| David Summers | Neuroradiologist        | Local investigator (reporting imaging) for the following trials – no involvement in designing trial protocol:<br>EORTC BR12 (randomised trial which compares standard PCV chemotherapy with two temozolomide schedules in patients with histologically confirmed recurrent World Health Organisation (WHO) Grade III or IV astrocytic tumour who have had primary radiotherapy (but no prior chemotherapy). Funded by CRUK. (Declared at recruitment) | Non-Personal, Financial, Specific | Declare and participate |

| Name          | Job title, organisation | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                  | Decision taken          |
|---------------|-------------------------|---|-----------------------------------|-------------------------|
| David Summers | Neuroradiologist        | Local investigator (reporting imaging) for the following trials – no involvement in designing trial protocol:<br>BR13 (Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas with stratification for genetic 1p loss: a phase III study). Funded by CRUK (Declared at recruitment) | Non-Personal, Financial, Specific | Declare and participate |
| David Summers | Neuroradiologist        | Local investigator (reporting imaging) for the following trials – no involvement in designing trial protocol:<br>BR14 (A Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in 1p/19q intact anaplastic glioma). Funded by CRUK (Declared at recruitment)   | Non-Personal, Financial, Specific | Declare and participate |
| David Summers | Neuroradiologist        | Local investigator (reporting imaging) for the following trials – no involvement in designing trial protocol:<br>EORTC1320 (Trabectedin for recurrent grade II or III meningioma: a randomized phase II study of the EORTC  | Non-Personal, Financial, Specific | Declare and participate |

| Name          | Job title, organisation | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                      | Decision taken          |
|---------------|-------------------------|--|---------------------------------------|-------------------------|
|               |                         | Brain Tumor Group.)<br>(Declared at recruitment)   |                                       |                         |
| David Summers | Neuroradiologist        | Local investigator (reporting imaging) for the following trials – no involvement in designing trial protocol:<br>CENTRIC (A multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone in glioblastoma<br>(Declared at recruitment) | Non-Personal, Financial, Specific     | Declare and participate |
| David Summers |                         | Local investigator (reporting imaging) for the following trials – no involvement in designing trial protocol:<br>CEREBEL (A Randomized, Multicentre, Open-Label, Phase III Study of Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in Patients with Anthracycline- or Taxane-Exposed ErbB2-Positive  | Non-Personal, Financial, Non-Specific | Declare and participate |

| Name          | Job title, organisation | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken          |
|---------------|-------------------------|---|---------------------------------------|-------------------------|
|               |                         | Metastatic Breast Cancer)<br>(Declared at recruitment)  |                                       |                         |
| David Summers | Neuroradiologist        | Local investigator (reporting imaging) for the following trials – no involvement in designing trial protocol:<br>INTELLANCE (A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification).<br>Funded by Radiation Therapy Oncology Group<br>(Declared at recruitment) | Non-Personal, Financial, Specific     | Declare and participate |
| David Summers | Neuroradiologist        | Radiologist on ACCESS trial (Molecular and Cellular Studies on Inflammation in Multiple Sclerosis).<br>Funded by Multiple Sclerosis Society (of Great Britain & Northern Ireland).<br>(Declared at recruitment)   | Personal, Non-Financial, Non-Specific | Declare and participate |
| David Summers | Neuroradiologist        | Radiologist on EXTEND trial (Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of   | Personal, Non-Financial, Non-Specific | Declare and participate |

| Name        | Job title, organisation                                     | Declarations of Interest, date declared (recruitment / committee meeting)  | Type of interest                  | Decision taken   |
|-------------|---|--|-----------------------------------|--|
|             |   | BIIB019). Funded by AbbVie. (Declared at recruitment)  |                                   |  |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Received a fee from Baxter for attending an advisory board on dural sealants in February 2016 (Declared at recruitment)  | Personal, Financial, Non-Specific | Declare and participate  |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Received sponsorship of travel from Medac to attend the Society of NeuroOncology meeting in November 2015 and the American Association of Neurosurgical Societies in May 2016. (Declared at recruitment)   | Personal, Financial, Non-Specific | Declare and participate  |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Chief investigator of the GALA-5 trial (An Evaluation of the Tolerability and Feasibility of combining 5-Amino-Levulinic Acid (5-ALA) with Carmustine Wafers (Gliadel) in the Surgical Management of Primary Glioblastoma). Funded by CRUK. Was involved in designing the trial protocol. Study has closed and being written up. (Declared at recruitment and committee meeting) | Non-Personal, Financial, Specific | Withdraw from all discussions on techniques for resection of glioma. |

| Name        | Job title, organisation                                     | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                      | Decision taken   |
|-------------|---|---|---------------------------------------|--|
|             |   | 14.06.2017.<br>15.06.2017)  |                                       |  |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Chief investigator of GALA BIDD trial (Improving the intra-operative diagnosis of high-grade glioma using a fluorescence biomarker). Funded by CRUK. Was involved in designing the trial protocol. (Declared at recruitment and committee meeting 14.06.2017. 15.06.2017) | Non-Personal, Financial, Specific     | Withdraw from all discussions on techniques for resection of glioma. |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Board member of British Neuro Oncology Society, European Association of Neuro-Oncology. (Declared at recruitment)   | Personal, Non-Financial, Non-Specific | Declare and participate  |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Chair of NCRI brain clinical subgroup and tumour section of the Society of British Neurosurgeons. (Declared at recruitment)   | Personal, Non-Financial, Non-Specific | Declare and participate  |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Head of the tumour section of the European Association of Neurosurgical Societies. (Declared at recruitment)  | Personal, Non-Financial, Non-Specific | Declare and participate  |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Consultant for MEDAC on pre-clinical trial of therapy. MEDAC make temozolomide  | Personal, Financial, Non-Specific     | Declare and participate  |

| Name        | Job title, organisation                                     | Declarations of Interest, date declared (recruitment / committee meeting)   | Type of interest                  | Decision taken          |
|-------------|---|---|-----------------------------------|-------------------------|
|             |   | and lomustine which are very likely to be considered in evidence reviews, but the specific product trialled will not be as it is in pre-clinical trials.<br>(Declared 17.11.2016)   |                                   |                         |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Advisory board Member Astra Zeneca. Relevant products made by Astra Zeneca include olaparib, but this would be out of scope.<br>(Declared 17.11.2016)   | Personal, Financial, Non-Specific | Declare and participate |
| Colin Watts | Clinical Senior Lecturer & Honorary Consultant Neurosurgeon | Made public comment on Tumour Treating Fields on Cancer Research UK press release on a trial published just prior to consultation, 'Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial'<br>(Declared 02.01.18) | Personal, Non-Financial, Specific | Declare and participate |

---

## NGA technical team

| NGA staff member   | Role   |
|--------------------|--|
| Alex Bates         | Guideline Lead   |
| Eva Gonzalez       | Systematic Reviewer (from September 2016)                      |
| Huayi Huang        | Systematic Reviewer (from September 2017)                      |
| James Hawkins      | Health Economist   |
| John Graham        | Clinical Advisor   |
| Katherine Andrea   | Senior Project Manager (from October 2017)                     |
| Katrina Blears     | Project Manager (until September 2016)                         |
| Kelly Williams     | Systematic Reviewer (from November 2016 until March 2017)      |
| Leanne Saxon       | Systematic Reviewer (from September 2016 until April 2017)     |
| Mia Schmidt-Hansen | Senior Systematic Reviewer (from February 2017)                |
| Natasha Pillai     | Systematic Reviewer (until November 2016)                      |
| Sabrina Naqvi      | Project Manager (from September 2016 until November 2016)      |
| Stephanie Arnold   | Information Scientist  |
| Victoria Rowlands  | Senior Project Manager (from November 2016 until October 2017) |

Additional support was received from Angela Bennett (Director of Guidelines), Annabel Flint (Senior Project Manager), Jennifer Francis (Project Administrator), Matthew Prettyjohns (Senior Health Economist), Méleshah Brown (Project Administrator) and Sally Humphreys (Project Manager)